Test Your Knowledge Question 1 In the REDEFINE 1 study (ClinicalTrials.gov Identifier: NCT05567796), semaglutide and cagrilintide dual therapy was favored over placebo for which of the following outcomes? Greater reductions in glucose area under the curve (AUC) Greater improvements in insulin resistance Greater reductions in HbA1c Greater improvements in body weight Question 4 What risk(s) do patients face when taking unapproved animal-derived thyroid medications? Your Answer: CORRECT INCORRECT Explanation: Greater reductions in glucose area under the curve (AUC). Although tirzepatide treatment was associated with significant reductions in glucose and insulin AUC across all glycemic subgroups during oral glucose tolerance testing, participants with prediabetes demonstrated greater reductions in glucose AUC. Reductions in HbA1c, fasting glucose, insulin, body weight, and insulin resistance were largely consistent across glycemic subgroups.